PPARG and inflammatory bowel disease: PPARγ agonists mitigate inflammatory bowel disease symptoms, reduce inflammation, and are effective in multiple models of ulcerative colitis as well as in Crohn’s disease [654,655,656,657,658,659,660,661,662,663,664,665,666,667].